Premium
Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases
Author(s) -
AppiahKubi Abena,
Acharya Suchitra,
Fein Levy Carolyn,
Vlachos Adrianna,
Ostovar Gholamabbas,
Murphy Kristina,
Farrell Antonella,
Brower Donna,
Lipton Jeffrey M.,
Wolfe Lawrence,
Aygun Banu
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17013
Subject(s) - medicine , acute chest syndrome , disease , epidemiology , splenectomy , hemoglobinopathy , pediatrics , pneumonia , intensive care medicine , immunology , sickle cell anemia , spleen
Patients with sickle cell disease (SCD) are theoretically at greater risk for serious illness from COVID 19 due to the underlying pathophysiology of chronic inflammation with an increased risk of thrombosis, especially at the time of a vaso-occlusive event (1). Individuals living with SCD are also considered to be immunocompromised due to autoinfarction of their spleen or surgical splenectomy, often as a result of red cell splenic sequestration (2). In addition, patients with SCD often have comorbidities and secondary organ dysfunction that can put them at risk of significant morbidity and or mortality from the severe acute respiratory coronavirus 2 (SARS-CoV-2), and its subsequent disease COVID-19.